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been no documented reports of the association between XPD-
Lys751Gln and nasopharyngeal carcinoma risk until now. The fre-
quency of the XRCC1 codon 280 homozygous wild-type Arg/Arg
genotype was 77.9% (88/113) in cases and 80.8% (105/130) in con-
trols; the heterozygous Arg/His genotype was 21.3% (24/113) in
cases and 18.5% (24/130) in controls; and the His/His genotype
was 0.8% (1/113) in cases and 0.7% (1/130) in controls. For XRCC1
codon 280 polymorphisms, no significant association between
Arg280His and risk of NPC was found (OR 1.30, 95% CI 0.66–2.57;
p = 0.447).
Interpretation: Risk of NPC was nearly two and a half times
higher for individuals with the homozygous wild-type Lys/Lys
genotype than for the heterozygous Lys/Gln genotype, adjusted
for age, sex, and ethnicity. To our knowledge, there have been
no documented reports of the association between XPDLys751Gln
and nasopharyngeal carcinoma risk until now.
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Background: We evaluated the safety and efficacy of nim-
otuzumab in combination with radiotherapy for oesophageal car-
cinoma (ESO).
Methods: 42 patients with stage II–IVa ESO were randomly
assigned as part of this prospective, phase 2 trial, fromNovember,
2008, to July, 2010. All patients received 50–70 Gy three-dimen-
sional conformal radiotherapy. 200 mg of nimotuzumab was
administered via intravenous infusion once a week during
radiotherapy.
Findings: Primary cancer lesions were located in the upper,
middle, and lower thoracic segments of the oesophagus in 10,
26, and 3 patients, respectively. Nine patients had stage II ESO,
25 had stage III, and eight had stage IVa. All patients received
50–70 Gy of radiation and 37 patients (88.1%) received nim-
otuzumab more than five times. Grade 3 toxicities were nausea
and vomiting (n = 1), oesophagitis (n = 3), skin reactions (n = 4),
and haematological toxicity (n = 1). One patient had an allergic
reaction to nimotuzumab. Four patients (9.5%) had a complete
response, 21 (50%) had a partial response, two (4.8%) had stable
disease, and 15 (35.7%) had progressive disease. The overall
disease control rate was 64.3%. With a median follow-up of 6
months, local recurrence was observed in six patients (14.3%)
and distance metastasis in ten (23.8%). Ten patients died, with
eight possible cancer-related deaths. The median survival time
has not yet been reached. 6-month and 1-year overall survival
rates were 82.4% and 57.8%.
Interpretation: Nimotuzumab in combination with radiother-
apy is well tolerated and effective for treatment of ESO. Long-term
toxicity and long-term efficacy require further evaluation.
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Background: Sentinel lymph node (SLN) mapping has recently
been introduced in the treatment of gastric cancer. Although
immunohistochemistry and conventional real-time PCR (RT-
qPCR) provide reliable information about micrometastases in
SLNs, they cannot examine large numbers of lymph nodes in a
short time, making them unfeasible for intraoperative use. The
SLN is defined as the first node to receive cancer-cell drainage
from the primary tumour, therefore micrometastases or isolated
tumour cells should first develop in these nodes. In this preli-
minary study, we evaluated the concept of single SLN screenings
for micrometastases by use of the Maruyama computer
program.
Methods: 23 patients were enrolled in our study: nine patients
were included in the control group and 14 in the study group. The
first stained lymph node was analysed with RT-qPCR for carcino-
embryonic antigen and CK-20 expression, as markers for microm-
etastases. Patients characteristics were retrospectively used as
predictors in the Maruyama computer program, to determine
the most likely metastatic site. Results were compared with the
actual staining patterns, and correlations between tumour char-
acteristics and micrometastases were examined.
Findings: 14 patients were found to be N0. Micrometastases
were detected in four patients (28.6%). In 76.9% of cases, extracted
SLNs coincided with lymph nodes predicted by the computer pro-
gram to be the most likely metastatic site. Micrometastases were
more common in Maruyama-predicted lymph nodes. Laurens
histological type distribution, preoperative CA 19-9 values, and
age distribution differed significantly between patients who were
positive and negative for micrometastases.
Interpretation: These results indicate the potential use of a sin-
gle SLN for intraoperative decision making; however, sensitivity
and specificity need to be evaluated in a larger series, supported
by long-term recurrence and survival results.
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